Patients in the clinical study received their infusion over 2 to 5 days. Your infusion may be given either at an infusion clinic or in your own home and will usually be given every 4 weeks.
In a clinical study, 95 adults with DM were given OCTAGAM 10% or placebo.
Patients in both treatment groups could continue taking their other medications while they were part of the study.
This study looked at patient improvements in muscle strength, amount of visible rash, activity level, quality of life, and protein levels in muscles.
There were 3 different categories that defined how much symptoms improved: minimal, moderate, and major.
All 3 improvement categories were measured after 16 weeks.
In a clinical study, the following side effects were reported by >5% of the patients:
Collapse
OCTAGAM 10% is indicated for the treatment of chronic immune thrombocytopenic purpura (cITP) in adults and dermatomyositis (DM) in adults. For patients with cITP, it is used to rapidly increase the platelet count in the blood to help control or prevent bleeding. For patients with DM, it helps improve muscle function and skin rash.
OCTAGAM 10% is a liquid medication that contains Immunoglobulin G (IgG). OCTAGAM 10% is made from human plasma donated by healthy people. OCTAGAM 10% is given through the vein (intravenously) in a hospital, infusion center, or at home.
Common side effects include headache, fever, nausea, vomiting, increased blood pressure, chills, musculoskeletal pain, dyspnea, infusion site reactions, and increased heart rate.
If you use a blood glucose monitor, check with your HCP to ensure that your monitor and test strips are acceptable to use while you are receiving OCTAGAM 10%.
These are not all of the possible side effects with OCTAGAM 10%. Tell your HCPs about any side effects that you have that cause concern or don't go away.
Please click here for Full Prescribing Information, including complete BOXED WARNING.
Patients should always ask their doctors for medical advice about adverse events.
You may report an adverse event related to Pfizer products by calling 1-800-438-1985 (US only). If you prefer, you may contact the US Food and Drug Administration (FDA) directly. The FDA has established a reporting service known as MedWatch where healthcare professionals and consumers can report problems they suspect may be associated with the drugs and medical devices they prescribe, dispense, or use. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.
OCTAGAM® is a registered trademark of Octapharma AG.
This site is intended only for U.S. residents. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only and is not intended to replace discussions with a healthcare provider.
Pfizer
PO Box 29309
Mission, KS 66201
Manufactured by Octapharma Pharmazeutika Produktionsges m.b.H.
Distributed by
Octapharma USA Inc.
PP-OTG-USA-0269-01
© 2023 Pfizer Inc.
December 2023
Expand
OCTAGAM 10% is indicated for the treatment of chronic immune thrombocytopenic purpura (cITP) in adults and dermatomyositis
(DM) in adults. For patients with cITP, it is used to rapidly increase the platelet count in the blood to
help control or prevent bleeding. For patients with DM, it helps improve muscle function and skin rash.
OCTAGAM 10% is a liquid medication that contains Immunoglobulin G (IgG). OCTAGAM 10% is made from human plasma donated by healthy people. OCTAGAM 10% is given through the vein (intravenously) in a hospital, infusion center, or at home.